ERBB2 and neoplasm: Taking into account the status of the primary tumor, HER2-negative patients with CK-positive/HER2-negative CTCs experienced a significantly decreased OS compared to patients with CK-positive/HER2-positive CTCs (17 months versus 42 months; p = 0.018).